All participants will be required to make payment through the website or in cash in order to confirm all bookings. Four weeks prior to departure, a 25% deposit of the total procedure price will be required to reserve booking.
Cancellation & Changes
Because of the special nature of the medical and tour packages featured in this Site, our affiliates may impose variable cancellation fees. You agree that our Company has no control over such fees and cannot consider making any exceptions to these charges. Cancellation policy will be mentioned in details for each quote.
In 2013–2014, new therapies, named DAAs, were developed and approved by the international authorities, FDA and European Medicine Agency, that act directly on hepatitis C virus at various points in the viral life cycle and therefore were able to reach above 90% success rates without the need for interferon in most cases and with minimal and tolerable side effects. They are currently approved and available in Egypt as part of the national campaign against hepatitis c.
The Egyptian NCCVH has adopted different protocols according to the different patient profiles and in alignment with the most recent international management guidelines [e.g., the American Association for the study of Disease (AASLD) and the European Association for the Study of the Liver (EASL)].
Available for treatment according to the case :
- – Sofosbuvir. ( Viropack 400)
- – Daclasavire. (Daclavirocryl 60 )
- – Sofosbuvir 400+ Ledipasvire 90. ( Viropack plus )
- – Ribavirin If needed
- – Qurevo for patients with renal impairment can be offered